scholarly journals Methylglyoxal stress induces a major epigenetic deregulation leading to a pro-migratory phenotype in breast cancer and significant clinical relevance

IBJ Plus ◽  
2021 ◽  
Author(s):  
◽  
◽  
Gaurav Dube ◽  
Martin Bizet ◽  
Rachel Deplus ◽  
...  
2018 ◽  
Author(s):  
M Banys-Paluchowski ◽  
K Milde-Langosch ◽  
T Fehm ◽  
I Witzel ◽  
L Oliveira-Ferrer ◽  
...  

2021 ◽  
Author(s):  
Samah A. Loutfy ◽  
Nasra F. Abdel Fattah ◽  
Ahmed B. Barakat ◽  
Omar R. Alfarouk ◽  
Tarek M. Hashem ◽  
...  

Breast Care ◽  
2008 ◽  
Vol 3 (1) ◽  
pp. 43-50 ◽  
Author(s):  
Hiltrud Brauch ◽  
Werner Schroth ◽  
Michel Eichelbaum ◽  
Matthias Schwab ◽  
Nadia Harbeck

2018 ◽  
Author(s):  
Soo-Hyun Kim ◽  
Richard P. Redvers ◽  
Lap Hing Chi ◽  
Xiawei Ling ◽  
Andrew J. Lucke ◽  
...  

ABSTRACTBreast cancer brain metastasis remains largely incurable. While several mouse models have been developed to investigate the genes and mechanisms regulating breast cancer brain metastasis, these models often lack clinical relevance since they require the use of immune-compromised mice and/or are poorly metastatic to brain from the mammary gland. We describe the development and characterisation of an aggressive brain metastatic variant of the 4T1 syngeneic model (4T1Br4) that spontaneously metastasises to multiple organs, but is selectively more metastatic to the brain from the mammary gland than parental 4T1 tumours. By immunohistochemistry, 4T1Br4 tumours and brain metastases display a triple negative phenotype, consistent with the high propensity of this breast cancer subtype to spread to brain. In vitro assays indicate that 4T1Br4 cells have an enhanced ability to adhere to or migrate across a brain-derived endothelial monolayer and greater invasive response to brain-derived soluble factors compared to 4T1 cells. These properties are likely to contribute to the brain-selectivity of 4T1Br4 tumours. Expression profiling and gene set enrichment analyses demonstrate the clinical relevance of the 4T1Br4 model at the transcriptomic level. Pathway analyses implicate tumour-intrinsic immune regulation and vascular interactions in successful brain colonisation, revealing potential therapeutic targets. Evaluation of two histone deacetylase inhibitors, SB939 and 1179.4b, shows partial efficacy against 4T1Br4 metastasis to brain and other sites in vivo and potent radio-sensitising properties in vitro. The 4T1Br4 model provides a clinically relevant tool for mechanistic studies and to evaluate novel therapies against brain metastasis.SUMMARY STATEMENTWe introduce a new syngeneic mouse model of spontaneous breast cancer brain metastasis, demonstrate its phenotypic, functional and transcriptomic relevance to human TNBC brain metastasis and test novel therapies.


Author(s):  
K. Pollow ◽  
H.-J. Grill ◽  
R. Kreienberg ◽  
G. Hoffmann ◽  
T. Beck ◽  
...  

2019 ◽  
Vol 179 (2) ◽  
pp. 403-414 ◽  
Author(s):  
Malgorzata Banys-Paluchowski ◽  
Karin Milde-Langosch ◽  
Tanja Fehm ◽  
Isabell Witzel ◽  
Leticia Oliveira-Ferrer ◽  
...  

Author(s):  
Beate Beer ◽  
Sabine Plattner ◽  
Michael Hubalek ◽  
Anne Oberguggenberger ◽  
Monika Sztankay ◽  
...  

AbstractThe application of cytochrome P450 2D6 (CYP2D6) genotyping to allow a personalized treatment approach for breast cancer patients undergoing endocrine therapy has been repeatedly discussed. However, the actual clinical relevance of the CYP2D6 genotype in the endocrine treatment of breast cancer still remains to be elucidated. A major prerequisite for the successful and valid evaluation of the CYP2D6 genotype with regard to its pharmacokinetic and clinical relevance is the availability of a comprehensive, accurate and cost-effective CYP2D6 genotyping strategy. Herein we present a CYP2D6 genotyping assay employing polymerase chain reaction (PCR)-ion pair reversed-phase high-performance liquid chromatography-electrospray ionization time-of-flight mass spectrometry (ICEMS). The genotyping strategy involves the simultaneous amplification of nine variable regions within the CYP2D6 gene by a two-step PCR protocol and the direct analysis of the generated PCR amplicons by ICEMS. The nucleotide composition profiles generated by ICEMS enable the differentiation of 37 of the 80 reported CYP2D6 alleles. The assay was applied to type the CYP2D6 gene in 199 Austrian individuals including 106 breast cancer patients undergoing tamoxifen treatment. The developed method turned out to be a highly applicable, robust and cost-effective approach, enabling an economical CYP2D6 testing for large patient cohorts.


Sign in / Sign up

Export Citation Format

Share Document